Neurodegenerative diseases represent a major public health problem, but beneficial clinical treatment with neurotrophic factors has not been established yet. The therapeutic use of neurotrophins has been restrained by their instability and rapid degradation in biological medium. A variety of strategies has been proposed for the administration of these leading therapeutic candidates, which are essential for the development, survival and function of human neurons. In this review, we describe the existing approaches for delivery of brain-derived neurotrophic factor (BDNF), which is the most abundant neurotrophin in the mammalian central nervous system (CNS). Biomimetic peptides of BDNF have emerged as a promising therapy against neurodegenerative disorders. Polymer-based carriers have provided sustained neurotrophin delivery, whereas lipid-based particles have contributed also to potentiation of the BDNF action. Nanotechnology offers new possibilities for the design of vehicles for neuroprotection and neuroregeneration. Recent developments in nanoscale carriers for encapsulation and transport of BDNF are highlighted.
References
[1]
Zuccato, C.; Cattaneo, E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol.？2009, 5, 311–322, doi:10.1038/nrneurol.2009.54.
[2]
Zuccato, C.; Cattaneo, E. Role of brain-derived neurotrophic factor in Huntington’s disease. Prog. Neurobiol.？2007, 81, 294–330, doi:10.1016/j.pneurobio.2007.01.003.
[3]
Fumagalli, F.; Molteni, R.; Calabrese, F.; Maj, P.F.; Racagni, G.; Riva, M.A. Neurotrophic factors in neurodegenerative disorders: Potential for therapy. CNS Drugs？2008, 22, 1005–1019, doi:10.2165/0023210-200822120-00004.
[4]
Balaratnasingam, S.; Janca, A. Brain derived neurotrophic factor: A novel neurotrophin involved in psychiatric and neurological disorders. Pharmacol. Ther.？2012, 134, 116–124, doi:10.1016/j.pharmthera.2012.01.006.
[5]
Nagahara, A.H.; Tuszynski, M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov.？2011, 10, 209–219, doi:10.1038/nrd3366.
Blesch, A. Neurotrophic factors in neurodegeneration. Brain Pathol.？2006, 16, 295–303, doi:10.1111/j.1750-3639.2006.00036.x.
[11]
Bekinschtein, P.; Cammarota, M.; Katche, C.; Slipczuk, L.; Rossato, J.I.; Goldin, A.; Lzquierdo, I.; Medina, J.H. BDNF is essential to promote persistence of long-term memory storage. Proc. Natl. Acad. Sci. USA？2008, 105, 2711–2716.
[12]
Bemelmans, A.P.; Horellou, P.; Pradier, L.; Brunet, I.; Colin, P.; Mallet, J. Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington’s disease, as demonstrated by adenoviral gene transfer. Hum. Gene Ther.？1999, 10, 2987–2997, doi:10.1089/10430349950016393.
[13]
Byerly, M.S.; Simon, J.; Lebihan-Duval, E.; Duclos, M.J.; Cogburn, L.A.; Porter, T.E. Effects of BDNF, NT-3, and corticosterone on expression of the hypothalamic obesity gene network in vivo and in vitro. Am. J. Physiol-Regul. Integr. Comp. Physiol.？2009, 296, R1180–R1189, doi:10.1152/ajpregu.90813.2008.
[14]
Canals, J.M.; Pineda, J.R.; Torres-Peraza, J.F.; Bosch, M.; Martin-Ibanez, R.; Munoz, M.T.; Mengod, G.; Ernfors, P.; Alberch, J. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington’s disease. J. Neurosci.？2004, 24, 7727–7739.
[15]
Cannon, T.D.; Yolken, R.; Buka, S.; Torrey, E.F. Collaborative study group on the perinatal origins of severe psychiatric disorders. Decreased neurotrophic response to birth hypoxia in the etiology of schizophrenia. Biol. Psychiatry？2008, 64, 797–802, doi:10.1016/j.biopsych.2008.04.012.
[16]
Castrén, E.; Rantam？ki, T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev. Neurobiol.？2010, 70, 289–297, doi:10.1002/dneu.20758.
[17]
Cattaneo, E.; Zuccato, C.; Tartari, M. Normal huntingtin function: An alternative approach to Huntington’s disease. Nat. Rev. Neurosci.？2005, 6, 919–930, doi:10.1038/nrn1806.
[18]
Zuccato, C.; Liber, D.; Ramos, C.; Tarditi, A.; Rigamonti, D.; Tartari, M.; Valenza, M.; Cattaneo, E. Progressive loss of BDNF in a mouse model of Huntington’s disease and rescue by BDNF delivery. Pharmacol. Res.？2005, 52, 133–139, doi:10.1016/j.phrs.2005.01.001.
[19]
Fumagalli, F.; Racagni, G.; Riva, M.A. The expanding role of BDNF: A therapeutic target for Alzheimer’s disease? Pharmacogenom. J.？2005, 6, 8–15, doi:10.1038/sj.tpj.6500337.
[20]
Galvao, R.; Garcia-Verdugo, J.M.; Alvarez-Buylla, A. Brain-derived neurotrophic factor signaling does not stimulate subventricular zone neurogenesis in adult mice and rats. J. Neurosci.？2008, 28, 13368–13383, doi:10.1523/JNEUROSCI.2918-08.2008.
[21]
Gielen, A.; Khademi, M.; Muhallab, S.; Olsson, T.; Piehl, F. Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients. Scand. J. Immunol.？2003, 57, 493–497, doi:10.1046/j.1365-3083.2003.01260.x.
[22]
Gomez-Pinilla, F. Brain foods: The effects of nutrients on brain function. Nat. Rev. Neurosci.？2008, 9, 568–578, doi:10.1038/nrn2421.
Liu, Q.R.; Walther, D.; Drgon, T.; Polesskaya, O.; Lesnick, T.G.; Strain, K.J.; de Andrade, M.; Bower, J.H.; Maraganore, D.M.; Uhl, G.R. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson’s disease. Am. J. Med. Genet. B Neuropsychiatr. Genet.？2005, 134B, 93–103, doi:10.1002/ajmg.b.30109.
[25]
Lipsky, R.H.; Marini, A.M. Brain-derived neurotrophic factor in neuronal survival and behavior-related plasticity. Ann. N. Y. Acad. Sci.？2007, 1122, 130–143, doi:10.1196/annals.1403.009.
[26]
Lu, Y.; Christian, K.; Lu, B. BDNF: A key regulator for protein synthesisdependent LTP and long-term memory? Neurobiol. Learn. Mem.？2008, 89, 312–323, doi:10.1016/j.nlm.2007.08.018.
[27]
Martinowich, K.; Manji, H.; Lu, B. New insights into BDNF function in depression and anxiety. Nat. Neurosci.？2007, 10, 1089–1093, doi:10.1038/nn1971.
[28]
Matsumoto, T.; Rauskolb, S.; Polack, M.; Klose, J.; Kolbeck, R.; Korte, M.; Barde, Y.A. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat. Neurosci.？2008, 11, 131–133.
[29]
Matsumoto, K.; Wada, R.K.; Yamashiro, J.M.; Kaplan, D.R.; Thiele, C.J. Expression of brain-derived neurotrophic factor and p145(TrkB) affects survival, differentiation and invasiveness of human neuroblastoma cells. Cancer Res.？1995, 55, 1798–1806.
[30]
Monteggia, L.M.; Barrot, M.; Powell, C.M.; Berton, O.; Galanis, V.; Gemelli, T.; Meuth, S.; Nagy, A.; Greene, R.W.; Nestler, E.J. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc. Natl. Acad. Sci. USA？2004, 101, 10827–10832.
[31]
Murer, M.G.; Yan, Q.; Raisman-Vozari, R. Brain-derived neurotrophic factor in the control humanbrain, and in Alzheimer’s disease and Parkinson’s disease. Prog. Neurobiol.？2001, 63, 71–124, doi:10.1016/S0301-0082(00)00014-9.
[32]
Nagahara, A.H.; Merrill, D.A.; Coppola, G.; Tsukada, S.; Schroeder, B.E.; Shaked, G.M.; Wang, L.; Blesch, A.; Kim, A.; Conner, J.M.; et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat. Med.？2009, 15, 331–337.
[33]
Nakagawa, T.; Ogawa, Y.; Ebihara, K.; Yamanaka, M.; Tsuchida, A.; Taiji, M.; Noguchi, H.; Nakao, K. Antiobesity and antidiabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance. Int. J. Obes.？2003, 27, 557–565, doi:10.1038/sj.ijo.0802265.
[34]
Nosheny, R.L.; Mocchetti, I.; Bachis, A. Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration. Neurotox. Res.？2005, 8, 187–198, doi:10.1007/BF03033829.
[35]
Perez-Navarro, E.; Alberch, J.; Neveu, I.; Arenas, E. Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo. Neuroscience？1999, 91, 1257–1264, doi:10.1016/S0306-4522(98)00723-4.
[36]
Pillai, A.; Mahadik, S.P. Increased truncated TrkB receptor expression and decreased BDNF/TrkB signaling in the frontal cortex of reeler mouse model of schizophrenia. Schizophr. Res.？2008, 100, 325–333, doi:10.1016/j.schres.2007.11.030.
[37]
Pillai, A. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia. Neurosignals？2008, 16, 183–193, doi:10.1159/000111562.
[38]
Rask-Andersen, M.; Olszewski, P.K.; Levine, A.S.; Schi？th, H.B. Molecular mechanisms underlying anorexia nervosa: Focus on human gene association studies and systems controlling food intake. Brain Res. Rev.？2010, 62, 147–164, doi:10.1016/j.brainresrev.2009.10.007.
[39]
Robinson, R.C.; Radziejewski, C.; Spraggon, G.; Greenwald, J.; Kostura, M.R.; Burtnick, L.D.; Stuart, D.I.; Choe, S.; Jones, E.Y. The structures of the neurotrophin-4 homodimer and the brain-derived neurotrophic factor/neurotrophin-4 heterodimer reveal a common Trk-binding site. Protein Sci.？1999, 8, 2589–2597.
Romero, M.I.; Rangappa, N.; Garry, M.G.; Smith, G.M. Functional regeneration of chronically injured sensory afferents into adult spinal cord after neurotrophin gene therapy. J. Neurosci.？2001, 21, 8408–8416.
[42]
Schabitz, W.R.; Berger, C.; Kollmar, R.; Seitz, M.; Tanay, E.; Kiessling, M.; Schwab, S.; Sommer, C. Effect of brain-derived neurotrophic factor treatment and forced arm use on functional motor recovery after small cortical ischemia. Stroke？2004, 35, 992–997, doi:10.1161/01.STR.0000119754.85848.0D.
[43]
Semkova, I.; Krieglstein, J. Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain Res.Brain Res. Rev.？1999, 30, 176–188, doi:10.1016/S0165-0173(99)00013-2.
[44]
Spina, M.B.; Squinto, S.P.; Miller, J.; Lindsay, R.M.; Hyman, C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity involvement of the glutathione system. J. Neurochem.？1992, 59, 99–106, doi:10.1111/j.1471-4159.1992.tb08880.x.
[45]
Stahl, K.; Mylonakou, M.N.; Skare, O.; Amiry-Moghaddam, M.; Torp, R. Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson’s disease. Brain Res.？2011, 1378, 105–118, doi:10.1016/j.brainres.2010.12.090.
[46]
Sun, Y.E.; Wu, H. The ups and downs of BDNF in Rett syndrome. Neuron？2006, 49, 321–323, doi:10.1016/j.neuron.2006.01.014.
[47]
The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology？1999, 52, 1427–1433.
[48]
Thompson, R.M.; Weickert, C.S.; Wyatt, E.; Webster, M.J. Decreased BDNF, trkB-TK and GAD67 mRNA expression in the hippocampus of individuals with chizophrenia and mood disorders. J. Psychiatry Neurosci.？2011, 36, 195–203, doi:10.1503/jpn.100048.
[49]
Tsai, S.J. TrkB partial agonists: Potential treatment strategy for epilepsy, mania, and autism. Med. Hypotheses？2006, 6, 173–175, doi:10.1016/j.mehy.2005.05.033.
[50]
Tsai, S.J. TrkB partial agonists: Potential treatment strategy for major depression. Med. Hypotheses？2007, 68, 674–676, doi:10.1016/j.mehy.2006.06.019.
Alfa, R.W.; Tuszynski, M.H.; Blesch, A. A novel inducible tyrosine kinase receptor to regulate signal transduction and neurite outgrowth. J. Neurosci. Res.？2009, 87, 2624–2631, doi:10.1002/jnr.22101.
[55]
Bariohay, B.; Roux, J.; Tardivel, C.; Trouslard, J.; Jean, A.; Lebrun, B. Brain-derived neurotrophic factor/tropomyosin-related kinase receptor type B signaling is a downstream effector of the brainstem melanocortin system in food intake control. Endocrinology？2009, 150, 2646–2653, doi:10.1210/en.2008-1184.
[56]
Boulle, F.; Kenis, G.; Cazorla, M.; Hamon, H.; Steinbusch, H.W.M.; Lanfumey, L.; van den Hove, D.L.A. TrkB inhibition as a therapeutic target for CNS-related disorders. Prog. Neurobiol.？2012, 98, 197–206, doi:10.1016/j.pneurobio.2012.06.002.
[57]
Chao, M.V.; Rajagopal, R.; Lee, F.S. Neurotrophin signalling in health anddisease. Clin. Sci.？2006, 110, 167–173, doi:10.1042/CS20050163.
[58]
Chen, G.; Manji, H.K. The extracellular signal-regulated kinase pathway: An emerging promising target for mood stabilizers. Curr. Opin. Psychiatry？2006, 19, 313–323, doi:10.1097/01.yco.0000218604.63463.cd.
[59]
Corominas, M.; Roncero, C.; Ribases, M.; Castells, X.; Casas, M. Brain-derived neurotrophic factor and its intracellular signaling pathways in cocaine addiction. Neuropsychobiology？2007, 55, 2–13, doi:10.1159/000103570.
[60]
Cowansage, K.K.; LeDoux, J.E.; Monfils, M.H. Brain-derived neurotrophic factor: A dynamic gatekeeper of neural plasticity. Curr. Mol. Pharmacol.？2010, 3, 12–29.
[61]
Desmet, C.J.; Peeper, D.S. The neurotrophic receptor TrkB: A drug target in anti-cancer therapy? Cell. Mol. Life Sci.？2006, 63, 755–759, doi:10.1007/s00018-005-5490-8.
[62]
Dwivedi, Y.; Rizavi, H.S.; Conley, R.R.; Roberts, R.C.; Tamminga, C.A.; Pandey, G.N. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch. Gen. Psychiatry？2003, 60, 804–815, doi:10.1001/archpsyc.60.8.804.
[63]
Ehrnhoefer, D.E.; Wong, B.K.Y.; Hayden, M.R. Convergent pathogenic pathways in Alzheimer’s and Huntington’s diseases: Shared targets for drug development. Nat. Rev. Drug Discov.？2011, 10, 853–867, doi:10.1038/nrd3556.
[64]
Elliott, E.; Atlas, R.; Lange, A.; Ginzburg, I. Brain-derived neurotrophic factor induces a rapid dephosphorylation of Tau protein through a PI-3 kinase signalling mechanism. Eur. J. Neurosci.？2005, 22, 1081–1089, doi:10.1111/j.1460-9568.2005.04290.x.
[65]
Hashimoto, K.; Koizumi, H.; Nakazato, M.; Shimizu, E.; Iyo, M. Role of brain-derived neurotrophic factor in eating disorders: Recent findings and its pathophysiological implications. Prog. Neuropsychopharmacol. Biol. Psychiatry？2005, 29, 499–504, doi:10.1016/j.pnpbp.2005.01.007.
[66]
He, X.P.; Kotloski, R.; Nef, S.; Luikart, B.W.; Parada, L.F.; McNamara, J.O. Conditional deletion of TrkB but not BDNF prevents epileptogenesis in the kindling model. Neuron？2005, 43, 31–42.
[67]
Kang, H.; Schuman, E.M. A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science？1996, 273, 1402–1406.
[68]
Nishida, Y.; Adati, N.; Ozawa, R.; Maeda, A.; Sakaki, Y.; Takeda, T. Identification and classification of genes regulated by phosphatidylinositol 3-kinase- and TrkB-mediated signalling pathways during neuronal differentiation in two subtypes of the human neuroblastoma cell line SH-SY5Y. BMC Res. Notes？2008, 1, 95, doi:10.1186/1756-0500-1-95.
[69]
Ibanez, C.F.; Ilag, L.L.; Murrayrust, J.; Persson, H. An extended surface of binding to Trk tyrosine kinase receptors in NGF and BDNF allows the engineering of a multifunctional pan-neurotrophin. EMBO J.？1993, 12, 2281–2293.
[70]
Jaboin, J.; Kim, C.J.; Kaplan, D.R.; Thiele, C.J. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Res.？2002, 62, 6756–6763.
[71]
Kermani, P.; Rafii, D.; Jin, D.K.; Whitlock, P.; Schaffer, W.; Chiang, A.; Vincent, L.; Friedrich, M.; Shido, K.; Hackett, N.R.; et al. Neurotrophins promote revascularization by local recruitment of TrkB(+) endothelial cells and systemic mobilization of hematopoietic progenitors. J. Clin. Invest.？2005, 115, 653–663.
[72]
Lessmann, V.; Gottmann, K.; Malcangio, M. Neurotrophin secretion: Current facts and future prospects. Prog. Neurobiol.？2003, 69, 341–374, doi:10.1016/S0301-0082(03)00019-4.
[73]
Malcangio, M.; Lessmann, V. A common thread for pain and memory synapses? Brain-derived neurotrophic factor and TrkB receptors. Trends Pharmacol. Sci.？2003, 24, 116–121, doi:10.1016/S0165-6147(03)00025-7.
[74]
Pattarawarapan, M.; Burgess, K. Molecular basis of neurotrophin-receptor interactions. J. Med. Chem.？2003, 46, 5277–5291, doi:10.1021/jm030221q.
[75]
Rantama？ki, T.; Hendolin, P.; Kankaanp？？, A.; Mijatovic, J.; Piepponen, P.; Domenici, E.; Chao, M.V.; M？nnist？, P.T.; Castrén, E. Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. Neuropsychopharmacology？2007, 32, 2152–2162, doi:10.1038/sj.npp.1301345.
Reichardt, L.F. Neurotrophin-regulated signalling pathways. Phil. Trans. R. Soc. B？2006, 361, 1545–1564.
[78]
Schramm, A.; Schulte, J.H.; Astrahantseff, K.; Apostolov, O.; van Limpt, V.; Sieverts, H.; Kuhfittig-Kulle, S.; Pfeiffer, P.; Versteeg, R.; Eggert, A. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett.？2005, 228, 143–153, doi:10.1016/j.canlet.2005.02.051.
[79]
Saarelainen, T.; Hendolin, P.; Lucas, G.; Koponen, E.; Sairanen, M.; MacDonald, E.; Agerman, K.; Haapasalo, A.; Nawa, H.; Aloyz, R.; et al. Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci.？2003, 23, 349–357.
[80]
Soliman, F.; Glatt, C.E.; Bath, K.G.; Levita, L.; Jones, R.M.; Pattwell, S.S.; Jing, D.; Tottenham, N.; Amso, D.; Somerville, L.H.; et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science？2010, 327, 863–866.
[81]
Waterhouse, E.G.; Xu, B. New insights into the role of brain-derived neurotrophic factor in synaptic plasticity. Mol. Cell Neurosci.？2009, 42, 81–89, doi:10.1016/j.mcn.2009.06.009.
[82]
Yang, T.; Yin, W.; Derevyanny, V.D.; Moore, L.A.; Longo, F.M. Identification of an ectodomain within the LAR protein tyrosine phosphatase receptor that binds homophilically and activates signalling pathways promoting neurite outgrowth. Eur. J. Neurosci.？2005, 22, 2159–2170, doi:10.1111/j.1460-9568.2005.04403.x.
[83]
Yoshii, A.; Constantine-Paton, M. Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev. Neurobiol.？2010, 70, 304–322.
[84]
Zhang, Q.; Liu, G.; Wu, Y.; Sha, H.; Zhang, P.; Jia, J. BDNF promotes EGF-induced proliferation and migration of human fetal neural stem/progenitor cells via the PI3K/Akt pathway. Molecules？2011, 16, 10146–10156, doi:10.3390/molecules161210146.
[85]
Frank, L.; Ventimiglia, R.; Anderson, K.; Lindsay, R.M.; Rudge, J.S. BDNF down-regulates neurotrophin responsiveness, TrkB protein and TrkB mRNA levels in cultured rat hippocampal neurons. Eur. J. Neurosci.？1996, 8, 1220–1230, doi:10.1111/j.1460-9568.1996.tb01290.x.
[86]
Knusel, B.; Gao, H.; Okazaki, T.; Yoshida, T.; Mori, N.; Hefti, F.; Kaplan, D.R. Ligand-induced down-regulation of Trk messenger RNA, protein and tyrosine phosphorylation in rat cortical neurons. Neuroscience？1997, 78, 851–862, doi:10.1016/S0306-4522(96)00616-1.
[87]
Sommerfeld, M.T.; Schweigreiter, R.; Barde, Y.A.; Hoppe, E. Downregulation of the neurotrophin receptor TrkB following ligand binding. Evidence for an involvement of the proteasome and differential regulation of TrkA and TrkB. J. Biol. Chem.？2000, 275, 8982–8990.
[88]
Agterberg, M.J.H.; Versnel, H.; van Dijk, L.M.; de Groot, J.; Klis, S.F.L. Enhanced survival of spiral ganglion cells after cessation of treatment with brain-derived neurotrophic factor in deafened guinea pigs. J. Assoc. Res. Otolaryngol.？2009, 10, 355–367, doi:10.1007/s10162-009-0170-2.
[89]
Ankeny, D.P.; McTigue, D.M.; Guan, Z.; Yan, Q.; Kinstler, O.; Stokes, B.T.; Jakeman, L.B. Pegylated brain-derived neurotrophic factor shows improved distribution into the spinal cord and stimulates locomotor activity and morphological changes after injury. Exp. Neurol.？2001, 170, 85–100.
[90]
Aubert-Pouessel, A.; Venier-Julienne, M.C.; Clavreul, A.; Sergent, M.; Jollivet, C.; Montero-Menei, C.N.; Garcion, E.; Bibby, D.C.; Menei, P.; Benoit, J.P. In vitro study of GDNF release from biodegradable PLGA microspheres. J. Control. Release？2004, 95, 463–475, doi:10.1016/j.jconrel.2003.12.012.
[91]
Alcala-Barraza, S.R.; Lee, M.S.; Hanson, L.R.; McDonald, A.A.; Frey, W.H., II; McLoon, L.K. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J. Drug Target.？2010, 18, 179–190, doi:10.3109/10611860903318134.
[92]
Barras, F.M.; Pasche, P.; Bouche, N.; Aebischer, P.; Zurn, A.D. Glial cell line-derived neurotrophic factor released by synthetic guidance channels promotes facial nerve regeneration in the rat. J. Neurosci. Res.？2002, 70, 746–755, doi:10.1002/jnr.10434.
[93]
Benoit, J.P.; Faisant, N.; Venier-Julienne, M.C.; Menei, P. Development of microspheres for neurological disorders: From basics to clinical applications. J. Control. Release？2000, 65, 285–296, doi:10.1016/S0168-3659(99)00250-3.
[94]
Bertram, J.P.; Rauch, M.F.; Chang, K.; Lavik, E.B. Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: Delivery of BDNF. Pharm. Res.？2010, 27, 82–91, doi:10.1007/s11095-009-0009-x.
[95]
Bauman, M.D.; Kang, C.E.; Stanwick, J.C.; Wang, Y.F.; Kim, H.; Lapitsky, Y.; Shoichet, M.S. An injectable dtug delivery platform for sustained combinatory therapy. J. Control. Release？2009, 138, 205–213, doi:10.1016/j.jconrel.2009.05.009.
[96]
Bloch, J.; Fine, E.G.; Bouche, N.; Zurn, A.D.; Aebischer, P. Nerve growth factor- and neurotrophin-3-releasing guidance channels promote regeneration of the transected rat dorsal root. Exp. Neurol.？2001, 172, 425–432.
[97]
Burdick, J.A.; Ward, M.; Liang, E.; Young, M.J.; Langer, R. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials？2006, 27, 452–459, doi:10.1016/j.biomaterials.2005.06.034.
[98]
Clavreul, A.; Sindji, L.; Aubert-Pouessel, A.; Benoi, J.P.; Menei, P.; Montero-Menei, C.N. Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts. Eur. J. Pharm. Biopharm.？2006, 63, 221–228, doi:10.1016/j.ejpb.2005.11.006.
[99]
Crigler, L.; Robey, R.C.; Asawachaicharn, A.; Gaupp, D.; Phinney, D.G. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp. Neurol.？2006, 198, 54–64, doi:10.1016/j.expneurol.2005.10.029.
[100]
Eriksdotter-Jonhagen, M. Local delivery of NGF to basal forebrain in AD patients. Alzheimers Dement.？2010, 6, S147–S148.
[101]
Fine, E.G.; Decosterd, I.; Papaloizos, M.; Zurn, A.D.; Aebischer, P. GDNF and NGF released by synthetic guidance channels support sciatic nerve regeneration across a long gap. Eur. J. Neurosci.？2002, 15, 589–601, doi:10.1046/j.1460-9568.2002.01892.x.
[102]
Fjord-Larsen, L.; Kusk, P.; Tornoe, J.; Juliusson, B.; Torp, M.; Bjarkam, C.R.; Nielsen, M.S.; Handberg, A.; Sorensen, J.C.H.; Wahlberg, L.U. Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the G？ttingen minipig basal forebrain. Molec. Ther.？2010, 18, 2164–2172, doi:10.1038/mt.2010.154.
[103]
Frim, D.M.; Uhler, T.A.; Galpern, W.R.; Beal, M.F.; Breakefield, X.O.; Icasson, O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. USA？1994, 91, 5104–5108.
Garbayo, E.; Montero-Menei, C.N.; Ansorena, E.; Lanciego, J.L.; Aymerich, M.S.; Blanco-Prieto, M.J. Effective GDNF brain delivery using microspheres—A promising strategy for Parkinson’s disease. J. Control. Release？2009, 135, 119–126, doi:10.1016/j.jconrel.2008.12.010.
[106]
Garbayo, E.; Ansorena, E.; Lanciego, J.L.; Blanco-Prieto, M.J.; Aymerich, M.S. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease. Mov. Disord.？2011, 26, 1943–1947, doi:10.1002/mds.23793.
[107]
Gill, S.S.; Patel, N.K.; Hotton, G.R.; O’Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J.; Svendsen, C.N.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson’s disease. Nat. Med.？2003, 12, 479–479.
[108]
Gomez, N.; Schmidt, C.E. Nerve growth factor-immobilized polypyrrole: Bioactive electrically conducting polymer for enhanced neurite extension. J. Biomed. Mater. Res. Part A？2006, 81A, 135–149, doi:10.1002/jbm.a.31047.
[109]
Guan, J.; Tong, W.; Ding, W.; Du, S.; Xiao, Z.; Han, Q.; Zhu, Z.; Bao, X.; Shi, X.; Wu, C.; et al. Neuronal regeneration and protection by collagen-binding BDNF in the rat middle cerebral artery occlusion model. Biomaterials？2012, 33, 1386–1395, doi:10.1016/j.biomaterials.2011.10.073.
[110]
Han, Q.Q.; Sun, W.J.; Lin, H.; Zhao, W.X.; Gao, Y.; Zhao, Y.N.; Chen, B.; Xiao, Z.F.; Hu, W.; Li, Y.; et al. Linear ordered collagen scaffolds loaded with collagen-binding brain-derived neurotrophic factor improve the recovery of spinal cord injury in rats. Tissue Eng. Part A？2009, 15, 2927–2935.
[111]
Hoshaw, B.A.; Malberg, J.E.; Lucki, I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res.？2005, 1037, 204–208, doi:10.1016/j.brainres.2005.01.007.
[112]
Houweling, D.A.; Lankhorst, A.J.; Gispen, W.H.; Bar, P.R.; Joosten, E.A.J. Collagen containing neurotrophin-3 (NT-3) attracts regrowing injured corticospinal axons in the adult rat spinal cord and promotes partial functional recovery. Exp. Neurol.？1998, 153, 49–59.
[113]
Jain, A.; Kim, Y.T.; McKeon, R.J.; Bellamkonda, R.V. In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials？2006, 27, 497–504, doi:10.1016/j.biomaterials.2005.07.008.
[114]
Jiang, Y.; Lv, H.; Huang, S.; Tan, H.; Zhang, Y.; Li, H. Bone marrow mesenchymal stem cells can improve the motor function of a Huntington’s disease rat model. Neurol. Res.？2011, 33, 331–337, doi:10.1179/016164110X12816242542571.
[115]
Jollivet, C.; Aubert-Pouessel, A.; Clavreul, A.; Venier-Julienne, M.C.; Montero-Menei, C.N.; Benoit, J.P.; Menei, P. Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease. Neurosci. Lett.？2004, 356, 207–210, doi:10.1016/j.neulet.2003.11.051.
[116]
Jollivet, C.; Aubert-Pouessel, A.; Clavreul, A.; Venier-Julienne, M.C.; Remy, S.; Montero-Menei, C.N.; Benoit, J.P.; Menei, P. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson’s disease. Biomaterials？2004, 25, 933–942, doi:10.1016/S0142-9612(03)00601-X.
[117]
Koda, M.; Kamada, T.; Hashimoto, M.; Murakami, M.; Shirasawa, H.; Sakao, S.; Ino, H.; Yoshinaga, K.; Koshizuka, S.; Moriya, H.; et al. Adenovirus vector-mediated ex vivo gene transfer of brain-derived neurotrophic factor to bone marrow stromal cells promotes axonal regeneration after transplantation in completely transected adult rat spinal cord. Eur. Spine J.？2007, 16, 2206–2214, doi:10.1007/s00586-007-0499-3.
[118]
Koda, M.; Hashimoto, M.; Murakami, M.; Yoshinaga, K.; Ikeda, O.; Yamazaki, M.; Koshizuka, S.; Kamada, T.; Moriya, H.; Shirasawa, H.; et al. Adenovirus vector-mediated in vivo gene transfer of brain-derived neurotrophic factor (BDNF) promotes rubrospinal axonal regeneration and functional recovery after complete transection of the adult rat spinal cord. J. Neurotrauma？2004, 21, 329–337, doi:10.1089/089771504322972112.
[119]
Kordower, J.H.; Palfi, S.; Chen, E.; Ma, S.; Sendera, T.; Cochran, E.J.; Mufson, E.J.; Penn, R.; Goetz, C.G.; Comella, C.D. Clinico-pathological findings following intraventricular GDNF treatment in patient with Parkinson’s disease. Ann. Neurol.？1999, 46, 419–424, doi:10.1002/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q.
[120]
Koennings, S.; Sapin, A.; Blunk, T.; Menei, P.; Goepferich, A. Towards controlled release of BDNF-manufacturing strategies for protein-loaded lipid implants and biocompatibility evaluation in the brain. J. Control. Release？2007, 119, 163–172, doi:10.1016/j.jconrel.2007.02.005.
[121]
Krewson, C.E.; Klarman, M.L.; Saltzman, W.M. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain Res.？1995, 680, 196–206, doi:10.1016/0006-8993(95)00261-N.
[122]
Kurakhmaeva, K.B.; Djindjikhashvili, I.A.; Petrov, V.E.; Balabanyan, V.U.; Voronina, T.A.; Trofimov, S.S.; Kreuter, J.; Gelperina, S.; Begley, D.; Alyautdin, R.N. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J. Drug Target.？2009, 17, 564–574, doi:10.1080/10611860903112842.
[123]
Lam, X.M.; Duenas, E.T.; Cleland, J.L. Encapsulation and stabilization of nerve growth factor into poly(lactic-co-glycolic) acid microspheres. J. Pharm. Sci.？2001, 90, 1356–1365, doi:10.1002/jps.1088.
Levivier, M.; Przedborski, S.; Bencsics, C.; Kang, U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease. J. Neurosci.？1995, 15, 7810–7820.
[128]
Li, L.-Y.; Li, J.-T.; Wu, Q.-Y.; Li, J.; Feng, Z.-T.; Liu, S.; Wang, T.-H. Transplantation of NGF-gene-modified bone marrow stromal cells into a rat model of Alzheimer’s disease. J. Mol. Neurosci.？2008, 34, 157–163, doi:10.1007/s12031-007-9022-x.
[129]
Malerba, F.; Paoletti, F.; Capsoni, S.; Cattaneo, A. Intranasal delivery of therapeutic proteins for neurological diseases. Expert Opin. Drug Deliv.？2011, 8, 1277–1296, doi:10.1517/17425247.2011.588204.
[130]
Maswood, N.; Young, J.; Tilmont, E.; Zhang, Z.M.; Gash, D.M.; Gerhardt, G.A.; Grondin, R.; Roth, G.S.; Mattison, J.; Lane, M.A.; et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson’s disease. Proc. Natl. Acad. Sci. USA？2004, 101, 18171–18176.
[131]
Maxwell, D.J.; Hicks, B.C.; Parsons, S.; Sakiyama-Elbert, S.E. Development of rationally designed affinity-based drug delivery systems. Acta Biomater.？2005, 1, 101–113, doi:10.1016/j.actbio.2004.09.002.
[132]
Maysinger, D.; Jalsenjak, I.; Cuello, A.C. Microencapsulated nerve growth factor: Effects on the forebrain neurons following devascularizing cortical lesions. Neurosci. Lett.？1992, 140, 71–74.
[133]
McGuinness, S.L.; Shepherd, R.K. Exogenous BDNF rescues rat spiral ganglion neurons in vivo. Otol. Neurol.？2005, 26, 1064–1072, doi:10.1097/01.mao.0000185063.20081.50.
Moloney, T.C.; Rooney, G.E.; Barry, F.P.; Howard, L.; Dowd, E. Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain. Brain Res.？2010, 1359, 33–43.
[136]
Moore, K.; Macsween, M.; Shoichet, M. Immobilized concentration gradients of neurotrophic factors guide neurite outgrowth of primary neurons in macroporous scaffolds. Tissue Eng.？2006, 12, 267–278, doi:10.1089/ten.2006.12.267.
[137]
Nakahara, Y.; Gage, F.H.; Tuszynski, M.H. Grafts of fibroblasts genetically modified to secrete NGF, BDNF, NT-3, or basic fgf elicit differential responses in the adult spinal cord. Cell. Transplant.？1996, 5, 191–204, doi:10.1016/0963-6897(95)02028-4.
[138]
Nomura, T.; Honmou, O.; Harada, K.; Houkin, K.; Hamada, H.; Kocsis, J.D. I.v. fusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Neuroscience？2005, 136, 161–169, doi:10.1016/j.neuroscience.2005.06.062.
Paradiso, B.; Marconi, P.; Zucchini, S.; Berto, E.; Binaschi, A.; Bozac, A.; Buzzi, A.; Mazzuferi, M.; Magri, E.; Mora, G.N.; et al. Localized delivery of fibroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc. Natl. Acad. Sci. USA？2009, 106, 7191–7196.
[141]
Pardridge, W.M.; Wu, D.F.; Sakane, T. Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm. Res.？1998, 15, 576–582, doi:10.1023/A:1011981927620.
[142]
Patist, C.M.; Mulder, M.B.; Gautier, S.E.; Maquet, V.; Jerome, R.; Oudega, M. Freeze-dried poly(D,L-lactic acid) macroporous guidance scaffolds impregnated with brain-derived neurotrophic factor in the transected adult rat thoracic spinal cord. Biomaterials？2004, 25, 1569–1582, doi:10.1016/S0142-9612(03)00503-9.
[143]
Pean, J.M.; Venier-Julienne, M.C.; Boury, F.; Menei, P.; Denizot, B.; Benoit, J.P. NGF release from poly(D,L-lactide-co-glycolide) microspheres: Effect of some formulation parameters on encapsulated NGF stability. J. Control. Release？1998, 56, 175–187.
[144]
Pean, J.M.; Venier-Julienne, M.C.; Filmon, R.; Sergent, M.; Phan-Tan-Luu, R.; Benoit, J.P. Optimization of HSA and NGF encapsulation yields in PLGA microparticles. Int. J. Pharm.？1998, 166, 105–115, doi:10.1016/S0378-5173(98)00033-7.
[145]
Piantino, J.; Burdick, J.A.; Goldberg, D.; Langer, R.; Benowitz, L.I. An injectable, biodegradable hydrogel for trophic factor delivery enhances axonal rewiring and improves performance after spinal cord injury. Exp. Neurol.？2006, 201, 359–367, doi:10.1016/j.expneurol.2006.04.020.
[146]
Richardson, R.T.; Thompson, B.; Moulton, S.; Newbold, C.; Lum, M.G.; Cameron, A.; Wallace, G.; Kapsa, R.; Clark, G.; O’Leary, S. The effect of polypyrrole with incorporated neurotrophin-3 on the promotion of neurite outgrowth from auditory neurons. Biomaterials？2007, 28, 513–523, doi:10.1016/j.biomaterials.2006.09.008.
[147]
Rosenberg, M.B.; Friedmann, T.; Robertson, R.C.; Tuszynski, M.; Wolff, J.A.; Breakefield, X.O.; Gage, F.H. Grafting genetically modified cells to the damaged brain: Restorative effects of NGF expression. Science？1998, 242, 1575–1578.
[148]
Sadan, O.; Bahat-Stromza, M.; Barhum, Y.; Levy, Y.S.; Pisnevsky, A.; Peretz, H.; Ilan, A.B.; Bulvik, S.; Shemesh, N.; Krepel, D.; et al. Protective effects of neurotrophic factors-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev.？2009, 18, 1179–1190, doi:10.1089/scd.2008.0411.
[149]
Sakane, T.; Pardridge, W.M. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm. Res.？1997, 14, 1085–1091, doi:10.1023/A:1012117815460.
[150]
Sakiyama-Elbert, S.E.; Hubbell, J.A. Controlled release of nerve growth factor from a heparin-containing fibrin-based cell ingrowth matrix. J. Control. Release？2000, 69, 149–158, doi:10.1016/S0168-3659(00)00296-0.
[151]
Sakiyama-Elbert, S.E.; Hubbell, J.A. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J. Control. Release？2000, 65, 389–402, doi:10.1016/S0168-3659(99)00221-7.
[152]
Sakiyama-Elbert, S.E.; Panitch, A.; Hubbell, J.A. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J.？2001, 15, 1300–1302.
[153]
Saltzman, W.M.; Mak, M.W.; Mahoney, M.J.; Duenas, E.T.; Cleland, J.L. Intracranial delivery of recombinant nerve growth factor: Release kinetics and protein distribution for three delivery systems. Pharm. Res.？1999, 16, 232–240, doi:10.1023/A:1018824324275.
[154]
Schabitz, W.R.; Schwab, S.; Spranger, M.; Hacke, W. Intraventricular brain-derived neurotrophic factor reduces infarct size after focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab.？1997, 17, 500–506.
[155]
Schabitz, W.R.; Sommer, C.; Zoder, W.; Kiessling, M.; Schwaninger, M.; Schwab, S. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Stroke？2000, 31, 2212–2217, doi:10.1161/01.STR.31.9.2212.
[156]
Scharfman, H.; Goodman, J.; Macleod, A.; Phani, S.; Antonelli, C.; Croll, S. Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. Exp. Neurol.？2005, 192, 348–356, doi:10.1016/j.expneurol.2004.11.016.
[157]
Sharma, H.S.; Sharma, A.; M？ssler, H.; Muresanu, D.F. Neuroprotective effects of cerebrolysin, a combination of different active fragments of neurotrophic factors and peptides on the whole body hyperthermia-induced neurotoxicity: Modulatory roles of co-morbidity factors and nanoparticle intoxication. Int. Rev. Neurobiol.？2012, 102, 249–276, doi:10.1016/B978-0-12-386986-9.00010-7.
[158]
Sirianni, R.W.; Olausson, P.; Chiu, A.S.; Taylor, J.R.; Saltzman, W.M. The behavioural and biochemical effects of BDNF containing polymers implanted in the hippocampus of rats. Brain Res.？2010, 1321, 40–50.
[159]
Slevin, J.T.; Gash, D.M.; Smith, C.D.; Gerhardt, G.A.; Kryscio, R.; Chebrolu, H.; Walton, A.; Wagner, R.; Young, B. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: Response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg.？2007, 106, 614–620, doi:10.3171/jns.2007.106.4.614.
[160]
Soderquist, R.G.; Milligan, E.D.; Sloane, E.M.; Harrison, J.A.; Douvas, K.K.; Potter, J.M.; Hughes, T.S.; Chavez, R.A.; Johnson, K.; Watkins, L.R.; et al. PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J. Biomed. Mater. Res. Part A？2009, 91A, 719–729, doi:10.1002/jbm.a.32254.
[161]
Somoza, R.; Juri, C.; Baes, M.; Wyneken, U.; Rubio, F.J. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: Implications for cell-based therapies in Parkinson’s disease. Biol. Blood Marrow Transplant.？2010, 16, 1530–1540, doi:10.1016/j.bbmt.2010.06.006.
[162]
Son, J.H.; Chun, H.S.; Joh, T.H.; Cho, S.; Conti, B.; Lee, J.W. Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J. Neurosci.？1999, 19, 10–20.
[163]
Stokols, S.; Tuszynski, M.H. Freeze-dried agarose scaffolds with uniaxial channels stimulate and guide linear axonal growth following spinal cord injury. Biomaterials？2006, 27, 443–451, doi:10.1016/j.biomaterials.2005.06.039.
[164]
Takeshima, Y.; Nakamura, M.; Miyake, H.; Tamaki, R.; Inui, T.; Horiuchi, K.; Wajima, D.; Nakase, H. Neuroprotection with intraventricular brain-derived neurotrophic factor in rat venous occlusion model. Neurosurgery？2011, 68, 1334–1341.
[165]
Taylor, L.; Jones, L.; Tuszynski, M.H.; Blesch, A. Neurotrophin-3 gradients established by lentiviral gene delivery promote short-distance axonal bridging beyond cellular grafts in the injured spinal cord. J. Neurosci.？2006, 26, 9713–9721, doi:10.1523/JNEUROSCI.0734-06.2006.
[166]
Taylor, S.J.; McDonald, J.W.; Sakiyama-Elbert, S.E. Controlled release of neurotrophin-3 from fibrin gels for spinal cord injury. J. Control. Release？2004, 98, 281–294, doi:10.1016/j.jconrel.2004.05.003.
[167]
Taylor, S.J.; Rosenzweig, E.S.; McDonald, J.W.; Sakiyama-Elbert, S.E. Delivery of neurotrophin-3 from fibrin enhances neuronal fiber sprouting after spinal cord injury. J. Control. Release？2006, 113, 226–235, doi:10.1016/j.jconrel.2006.05.005.
[168]
Taylor, S.J.; Sakiyama-Elbert, S.E. Effect of controlled delivery of neurotrophin-3 from fibrin on spinal cord injury in a long term model. J. Control. Release？2006, 116, 204–210, doi:10.1016/j.jconrel.2006.07.005.
[169]
Thompson, B.C.; Moulton, S.E.; Ding, J.; Richardson, R.; Cameron, A.; O’Leary, S.; Wallace, G.G.; Clark, G.M. Optimising the incorporation and release of a neurotrophic factor using conducting polypyrrole. J. Control. Release？2006, 116, 285–294, doi:10.1016/j.jconrel.2006.09.004.
[170]
Vogelin, E.; Baker, J.M.; Gates, J.; Dixit, V.; Constantinescu, M.A.; Jones, N.F. Effects of local continuous release of brain derived neurotrophic factor (BDNF) on peripheral nerve regeneration in a rat model. Exp. Neurol.？2006, 199, 348–353, doi:10.1016/j.expneurol.2005.12.029.
[171]
Willerth, S.M.; Johnson, P.J.; Maxwell, D.J.; Parsons, S.R.; Doukas, M.E.; Sakiyama-Elbert, S.E. Rationally designed peptides for controlled release of nerve growth factor from fibrin matrices. J. Biomed. Mater. Res. Part A？2006, 80A, 13–23.
[172]
Williams, G.; Williams, E.J.; Maison, P.; Pangalos, M.N.; Walsh, F.S.; Doherty, P. Overcoming the inhibitors of myelin with a novel neurotrophin strategy. J. Biol. Chem.？2005, 280, 5862–5869.
[173]
Winter, J.O.; Cogan, S.F.; Rizzo, J.F. Neurotrophin-eluting hydrogel coatings for neural stimulating electrodes. J. Biomed. Mater. Res. Part B？2007, 81B, 551–563, doi:10.1002/jbm.b.30696.
[174]
Wu, D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx？2005, 2, 120–128, doi:10.1602/neurorx.2.1.120.
[175]
Wu, D.F.; Pardridge, W.M. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc. Natl. Acad. Sci. USA？1999, 96, 254–259, doi:10.1073/pnas.96.1.254.
[176]
Xie, Y.; Ye, L.Y.; Zhang, X.B.; Cui, W.; Lou, J.N.; Nagai, T.; Hou, X.P. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: In vitro and in vivo studies. J. Control. Release？2005, 105, 106–119, doi:10.1016/j.jconrel.2005.03.005.
[177]
Xu, X.Y.; Yee, W.C.; Hwang, P.Y.K.; Yu, H.; Wan, A.C.A.; Gao, S.J.; Boon, K.L.; Mao, H.Q.; Leong, K.W.; Wang, S. Peripheral nerve regeneration with sustained release of poly(phosphoester) microencapsulated nerve growth factor within nerve guide conduits. Biomaterials？2003, 24, 2405–2412, doi:10.1016/S0142-9612(03)00109-1.
[178]
Yamashita, K.; Wiessner, C.; Lindholm, D.; Thoenen, H.; Hossmann, K.A. Post-occlusion treatment with BDNF reduces infarct size in a model of permanent occlusion of the middle cerebral artery in rat. Metab. Brain Dis.？1997, 12, 271–280.
[179]
Yang, K.; Clifton, G.L.; Hayes, R.L. Gene therapy for central nervous system injury: The use of cationic liposomes. J. Neurotrauma？1997, 14, 281–297, doi:10.1089/neu.1997.14.281.
[180]
Yang, Y.; De Laporte, L.; Rives, C.B.; Jang, J.H.; Lin, W.C.; Shull, K.R.; Shea, L.D. Neurotrophin releasing single and multiple lumen nerve conduits. J. Control. Release？2005, 104, 433–446, doi:10.1016/j.jconrel.2005.02.022.
[181]
Yu, X.J.; Bellamkonda, R.V. Tissue-engineered scaffolds are effective alternatives to autografts for bridging peripheral nerve gaps. Tissue Eng.？2003, 9, 421–430, doi:10.1089/107632703322066606.
[182]
Yu, X.J.; Dillon, G.P.; Bellamkonda, R.V. A laminin and nerve growth factor-laden three-dimensional scaffold for enhanced neurite extension. Tissue Eng.？1999, 5, 291–304, doi:10.1089/ten.1999.5.291.
[183]
Zhang, Y.; Pardridge, W.M. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res.？2001, 889, 49–56.
[184]
Bachoud-Levi, A.C.; Deglon, N.; Nguyen, J.P.; Bloch, J.; Bourdet, C.; Winkel, L.; Rémy, P.; Goddard, M.; Lefaucheur, J.-P.; Brugières, P.; et al. Neuroprotective gene therapy for Huntington’s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum. Gene Ther.？2000, 11, 1723–1729, doi:10.1089/10430340050111377.
[185]
Bergen, J.M.; Park, I.K.; Horner, P.J.; Pun, S.H. Nonviral approaches for neuronal delivery of nucleic acids. Pharm. Res.？2008, 25, 983–998, doi:10.1007/s11095-007-9439-5.
[186]
Blesch, A. Neurotrophin gene therapy for Alzheimer’s disease. Future Neurol.？2006, 1, 179–187, doi:10.2217/14796708.1.2.179.
[187]
Blesch, A. MLV based retroviral and lentiviral vectors for in vitro and in vivo gene transfer. Methods？2004, 33, 164–172, doi:10.1016/j.ymeth.2003.11.005.
[188]
Bloch, J.; Bachoud-Levi, A.C.; Deglon, N.; Lefaucheur, J.P.; Winkel, L.; Palfi, S.; Nguyen, J.P.; Bourdet, C.; Gaura, V.; Remy, P.; et al. Neuroprotective gene therapy for Huntington’s disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: Results of a phase I study. Hum. Gene Ther.？2004, 15, 968–975, doi:10.1089/hum.2004.15.968.
[189]
Bjorklund, T.; Kirik, D. Scientific rationale for the development of gene therapy strategies for Parkinson’s disease. Biochim. Biophys. Acta？2009, 1792, 703–713, doi:10.1016/j.bbadis.2009.02.009.
Bowers, W.J.; Breakefield, X.O.; Sena-Esteves, M. Genetic therapy for the nervous system. Hum. Molec. Gen.？2011, 20, R28–R41, doi:10.1093/hmg/ddr110.
[192]
Di Polo, A.; Aigner, L.J.; Dunn, R.J.; Bray, G.M.; Aguayo, A.J. Prolonged delivery of brain-derived neurotrophic factor by adenovirus-infected Muller cells temporarily rescues injured retinal ganglion cells. Proc. Nat. Acad. Sci. USA？1998, 95, 3978–3983.
[193]
Henry, R.A.; Hughes, S.M.; Connor, B. AAV-mediated delivery of BDNF augments neurogenesis in the normal and quinolinic acid-lesioned adult rat brain. Eur. J. Neurosci.？2007, 25, 3513–3525, doi:10.1111/j.1460-9568.2007.05625.x.
[194]
Kells, A.P.; Fong, D.M.; Dragunow, M.; During, M.J.; Young, D.; Connoet, B. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol. Ther.？2004, 9, 682–688, doi:10.1016/j.ymthe.2004.02.016.
[195]
Lu, K.W.; Chen, Z.Y.; Jin, D.D.; Hou, T.S.; Cao, L.; Fu, Q. Cationic liposome-mediated GDNF gene transfer after spinal cord injury. J. Neurotrauma？2002, 19, 1081–1090, doi:10.1089/089771502760341983.
[196]
Lu, P.; Jones, L.L.; Tuszynski, M.H. BDNF-expressing marrow stromal cells support extensive axonal growth at sites of spinal cord injury. Exp. Neurol.？2005, 191, 344–360, doi:10.1016/j.expneurol.2004.09.018.
[197]
Makar, T.K.; Bever, C.T.; Singh, I.S.; Royal, W.; Sahu, S.N.; Sura, T.P.; Sultana, S.; Sura, K.T.; Patel, N.; Dhib-Jalbut, S.; et al. Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J. Neuroimmunol.？2009, 210, 40–51, doi:10.1016/j.jneuroim.2009.02.017.
[198]
Munehisa, S.; Naoyuki, S.; Ryuichi, M. Experimental and clinical application of plasmid DNA in the field of central nervous diseases. Curr. Gene Ther.？2011, 11, 491–500, doi:10.2174/156652311798192833.
[199]
Nakajima, H.; Uchida, K.; Yayama, T.; Kobayashi, S.; Guerrero, A.R.; Furukawa, S.; Baba, H. Targeted retrograde gene delivery of brain-derived neurotrophic factor supresses apoptosis and oligodendrolia after spinal cord injury in rats. Spine？2010, 35, 497–504, doi:10.1097/BRS.0b013e3181b8e89b.
Park, H.Y.L.; Kim, J.H.K.; Kim, H.S.; Park, C.K. Stem cell-based delivery of brain-derived neurotrophic factor gene in the rat retina. Brain Res.？2012, 1469, 10–23, doi:10.1016/j.brainres.2012.06.006.
[202]
Sayers, S.T.; Khan, N.; Ahmed, Y.; Shahid, R.; Khan, T. Preparation of brain-derived neurotrophic factor- and neurotrophin-3-secreting Schwann cells by infection with a retroviral vector. J. Mol. Neurosci.？1998, 10, 143–160, doi:10.1007/BF02737125.
[203]
Tuszynski, M.H.; Thal, L.; Pay, M.; Salmon, D.P.; Sang, U.H.; Bakay, R.; Patel, P.; Blesch, A.; Vahlsing, H.L.; Ho, G.; et al. A phase I clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med.？2005, 11, 551–555, doi:10.1038/nm1239.
Price, R.D.; Milne, S.A.; Sharkey, J.; Matsuoka, N. Advances in small molecules promoting neurotrophic function. Pharmacol. Ther.？2007, 115, 292–306, doi:10.1016/j.pharmthera.2007.03.005.
[217]
Tuinstra, H.M.; Aviles, M.O.; Shin, S.; Holland, S.J.; Zelivyanskaya, M.L.; Fast, A.G.; Ko, S.Y.; Margul, D.J.; Bartels, A.K.; Boehler, R.M.; et al. Multifunctional, multichannel bridges that deliver neurotrophin encoding lentivirus for regeneration following spinal cord injury. Biomaterials？2012, 33, 1618–1626.
[218]
Park, J.; Lim, E.; Back, S.; Na, H.; Park, Y.; Sun, K. Nerve regeneration following spinal cord injury using matrix metalloproteinase-sensitive, hyaluronic acid-based biomimetic hydrogel scaffold containing brain-derived neurotrophic factor. J. Biomed. Mater. Res. A？2010, 93, 1091–1099.
[219]
Géral, C.; Angelova, A.; Angelov, B.; Nicolas, V.; Lesieur, S. Multicompartment lipid nanocarriers for targeting of cells expressing brain receptors. In Self-Assembled Supramolecular Architectures: Lyotropic Liquid Crystals; Garti, N., Mezzenga, R., Somasundaran, P., Eds.; John Wiley & Sons, Inc.: New Jersey, NJ, USA, 2012; pp. 319–355.
[220]
Eriksdotter-J？nhagen, M.; Nordberg, A.; Amberla, K.; B？ckman, L.; Ebendal, T.; Meyerson, B.; Olson, L.; Seiger, A.; Shigeta, M.; Theodorsson, E.; et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.？1998, 9, 246–257, doi:10.1159/000017069.
[221]
Seiger, A.; Nordberg, A.; von Holst, H.; B？ckman, L.; Ebendal, T.; Alafuzoff, I.; Amberla, K.; Hartvig, P.; Herlitz, A.; Lilja, A.; et al. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. Behav. Brain Res.？1993, 57, 255–261, doi:10.1016/0166-4328(93)90141-C.
Allen, S.J.; Robertson, A.G.S.; Tyler, S.J.; Wilcock, G.K.; Dawbarn, D. Recombinant human nerve growth factor for clinical trials: Protein expression, purification, stability and characterisation of binding to infusion pumps. J. Biochem. Biophys. Methods？2001, 47, 239–255, doi:10.1016/S0165-022X(01)00134-8.
[224]
Blurton-Jones, M.; Kitazawa, M.; Martinez-Coria, H.; Castello, N.A.; Mueller, F.-J.; Loring, J.F.; Yamasaki, T.R.; Poon, W.W.; Green, K.N.; LaFerla, F.M. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. USA？2009, 32, 13594–13599.
[225]
Wahlberg, L.U.; Lind, G.; Almqvist, P.M.; Kusk, P.; Torn？e, J.; Juliusson, B.; S？derman, M.; Selldén, E.; Seiger, A.; Eriksdotter-J？nhagen, M.; et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: A technology platform for restorative neurosurgery. J. Neurosurgery？2012, 117, 340–347, doi:10.3171/2012.2.JNS11714.
[226]
Brahimi, F.; Malakhov, A.; Lee, H.B.; Pattarawarapan, M.; Ivanisevic, L.; Burgess, K.; Saragovi, H.U. A peptidomimetic of NT-3 acts as a TrkC antagonist. Peptides？2009, 30, 1833–1839, doi:10.1016/j.peptides.2009.07.015.
[227]
Peleshok, J.; Saragovi, H.U. Functional mimetics of neurotrophins and their receptors. Biochem. Soc. Trans.？2006, 34, 612–617, doi:10.1042/BST0340612.
[228]
Webster, N.J.G.; Pirrung, M.C. Small molecule activators of the Trk receptors for neuroprotection. BMC Neuroscience？2008, 9, S1:1–S1:8.
[229]
Adessi, C.; Soto, C. Converting a peptide into a drug: Strategies to improve stability and bioavailability. Curr. Med. Chem.？2002, 9, 963–978, doi:10.2174/0929867024606731.
[230]
Begley, D.J. Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol. Ther.？2004, 104, 29–45, doi:10.1016/j.pharmthera.2004.08.001.
[231]
Boado, R.J.; Pardridge, W.M. The Trojan horse liposome technology for nonviral gene transfer across the blood-brain barrier. J. Drug Deliv.？2011, 2011, 296151:1–296151:12.
[232]
Xia, C.F.; Boado, R.J.; Zhang, Y.; Chu, C.; Pardridge, W.M. Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson’s disease with Trojan horse liposomes and a tyrosine hydroxylase promoter. J. Gene Med.？2008, 10, 306–315, doi:10.1002/jgm.1152.
[233]
Craparo, E.F.; Bondi, M.L.; Pitarresi, G.; Cavallaro, G. Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci. Therapeutics？2011, 17, 670–677, doi:10.1111/j.1755-5949.2010.00199.x.
[234]
Hughes, G.A. Nanostructure-mediated drug delivery. Nanomed. Nanotech. Biol. Med.？2005, 1, 22–30, doi:10.1016/j.nano.2004.11.009.
[235]
Kanwar, J.R.; Sun, X.; Punj, V.; Sriramoju, B.; Mohan, R.R.; Zhou, S.F.; Chauhan, A.; Kanwar, R.K. Nanoparticles in the treatment and diagnosis of neurological disorders: Untamed dragon with fire power to heal. Nanomed. Nanotech. Biol. Med.？2012, 8, 399–414, doi:10.1016/j.nano.2011.08.006.
[236]
Koo, O.M.; Rubinstein, I.; Onyuksel, H. Role of nanotechnology in targeted drug delivery and imaging. Nanomed. Nanotech. Biol. Med.？2005, 1, 193–212.
[237]
Modi, G.; Pillay, V.; Choonara, Y.E.; Ndesendo, V.M.; du Toit, L.C.; Naidoo, D. Nanotechnologicalapplications for the treatment of neurodegenerative disorders. Prog. Neurobiol.？2009, 88, 272–285, doi:10.1016/j.pneurobio.2009.05.002.
[238]
Nunes, A.; Al-Jamal, K.T.; Kostarelos, K. Therapeutics, imaging and toxicity of nanomaterials in the central nervous system. J. Control. Release？2012, 161, 290–306, doi:10.1016/j.jconrel.2012.03.026.
[239]
Paolino, D.; Cosco, D.; Molinaro, R.; Celia, C.; Fresta, M. Supramolecular devices to improve the treatment of brain diseases. Drug Discov. Today？2011, 16, 311–324, doi:10.1016/j.drudis.2011.02.006.
[240]
Wong, H.L.; Wu, X.Y.; Bendayan, R. Nanotechnological advances for the delivery of CNS therapeutics. Adv. Drug Deliv. Rev.？2012, 64, 686–700, doi:10.1016/j.addr.2011.10.007.
[241]
Wang, Y.; Huang, L. Multifunctional theranostic nanoparticles for brain tumors. Mol. Ther.？2012, 20, 10–11, doi:10.1038/mt.2011.274.
[242]
Patel, M.M.; Goyal, B.R.; Bhadada, S.V.; Bhat, J.S.; Amin, A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs？2009, 23, 35–58.
[243]
Petros, R.A.; DeSimone, J.M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov.？2010, 9, 615–627, doi:10.1038/nrd2591.
Schnyder, A.; Huwyler, J. Drug transport to brain with targeted liposomes. NeuroRx？2005, 2, 99–107, doi:10.1602/neurorx.2.1.99.
[246]
Zhang, S.; Uludag, H. Nanoparticulate systems for growth factor delivery. Pharm. Res.？2009, 26, 1561–1580, doi:10.1007/s11095-009-9897-z.
[247]
Mehrotra, S.; Lynam, D.; Maloney, R.; Pawelec, K.M.; Tuszynski, M.H.; Lee, I.; Chan, C.; Sakamoto, J. Time controlled protein release from layer-by-layer assembled multilayer functionalized agarose hydrogels. Adv. Funct. Mater.？2010, 20, 247–258.
[248]
Pang, Z.; Lu, W.; Gao, H.; Hu, K.; Chen, J.; Zhang, C.; Gao, X.; Jiang, X.; Zhu, C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control. Release？2008, 128, 120–127, doi:10.1016/j.jconrel.2008.03.007.
[249]
Bickel, U.; Yoshikawa, T.; Pardridge, W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev.？2001, 46, 247–279, doi:10.1016/S0169-409X(00)00139-3.
[250]
Pardridge, W.M. Vector-mediated peptide drug delivery to the brain. Adv. Drug Deliv. Rev.？1995, 15, 109–146, doi:10.1016/0169-409X(95)00007-T.
[251]
Pardgridge, W.M. Biopharmaceutical drug targeting to the brain. J. Drug Target.？2010, 18, 157–167, doi:10.3109/10611860903548354.
[252]
Pardridge, W.M. Re-engineering bioPharmaceutics for delivery to brain with molecular Trojan horses. Bioconjugate Chem.？2008, 19, 1327–1338.
[253]
Boado, R.J.; Zhang, Y.; Zhang, Y.; Pardridge, W.M. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol. Bioeng.？2007, 97, 1376–1386, doi:10.1002/bit.21369.
[254]
Tan, J.; Wang, Y.; Yip, X.; Glynn, F.; Shepherd, R.K.; Caruso, F. Nanoporous peptide particles for encapsulating and releasing neurotrophic factors in an animal model of neurodegeneration. Adv. Mater.？2012, 24, 3362–3366, doi:10.1002/adma.201200634.
Roy, S.; Johnston, A.H.; Newman, T.A.; Glueckert, R.; Dudas, J.; Bitsche, M.; Corbacella, E.; Rieger, G.; Martini, A.; Schrott-Fischer, A. Cell-specific targeting in the mouse inner ear using nanoparticles conjugated with a neurotrophin-derived peptide ligand: Potential tool for drug delivery. Int. J. Pharm.？2010, 390, 214–224, doi:10.1016/j.ijpharm.2010.02.003.
[257]
Angelov, B.; Angelova, A.; Filippov, S.; Karlsson, G.; Terrill, N.; Lesieur, S.; ？těpánek, P. Topology and internal structure of PEGylated lipid nanocarriers for neuronal transfection: Synchrotron radiation SAXS and cryo-TEM studies. Soft Matter.？2011, 7, 9714–9720, doi:10.1039/c1sm06447a.
[258]
Angelov, B.; Angelova, A.; Filippov, S.; Karlsson, G.; Terrill, N.; Lesieur, S.; ？těpánek, P. SAXS study of sterically stabilized lipid nanocarriers functionalized by DNA. J. Phys. Conf. Series？2012, 351, 012004:1–012004:9.
[259]
Wu, H.; Li, J.; Zhang, Q.; Yan, X.; Guo, L.; Gao, X.; Qiu, M.; Jiang, X.; Lai, R.; Chen, H. A novel small Odorranalectin-bearing cubosomes: Preparation, brain delivery and pharmacodynamic study on amyloid-b25–35-treated rats following intranasal administration. Eur. J. Pharm. Biopharm.？2012, 80, 368–378, doi:10.1016/j.ejpb.2011.10.012.
[260]
Cornford, E.M.; Cornford, M.E. New systems for delivery of drugs to the brain in neurological diseases. Lancet Neurol.？2002, 1, 306–315, doi:10.1016/S1474-4422(02)00136-9.
[261]
Kabanov, A.V.; Gendelman, H.E. Nanomedicine in the diagnosis and therapy of neurodegeneratve disorders. Prog. Polym. Sci.？2007, 32, 1054–1082, doi:10.1016/j.progpolymsci.2007.05.014.
[262]
Buse, J.; El-Aneed, A. Properties, engineering and applications of lipid-based nanoparticle drug-delivery systems: Current research and advances. Nanomedicine？2010, 5, 1237–1260, doi:10.2217/nnm.10.107.
[263]
Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov.？2005, 4, 145–160, doi:10.1038/nrd1632.
[264]
Cortesi, R.; Esposito, E.; Corradini, F.; Sivieri, E.; Drechsler, M.; Rossi, A.; Scatturin, A.; Menegatti, E. Non-phospholipid vesicles as carriers for peptides and proteins: Production, characterization and stability studies. Int. J. Pharm.？2007, 339, 52–60.
[265]
Angelova, A.; Angelov, B.; Papahadjopoulos-Sternberg, B.; Ollivon, M.; Bourgaux, C. Proteocubosomes: Nanoporous vehicles with tertiary organized fluid interfaces. Langmuir？2005, 21, 4138–4143, doi:10.1021/la047745t.
[266]
Angelova, A.; Ollivon, M.; Campitelli, A.; Bourgaux, C. Lipid cubic phases as stable nanochannel network structures for protein biochip development: X-ray diffraction study. Langmuir？2003, 19, 6928–6935.
[267]
Angelova, A.; Angelov, B.; Papahadjopoulos-Sternberg, B.; Bourgaux, C.; Couvreur, P. Protein driven patterning of self-assembled cubosomic nanostructures: Long oriented nanoridges. J. Phys. Chem. B？2005, 109, 3089–3093.
[268]
Aota-Nakano, U.; Li, S.J.; Yamazaki, M. Effects of electrostatic interaction on the phase stability and structures of cubic phases of monoolein/oleic acid mixture membranes. Biochim. Biophys. Acta-Biomembr.？1999, 1461, 96–102, doi:10.1016/S0005-2736(99)00156-X.
[269]
Barauskas, J.; Johnsson, M.; Johnson, F.; Tiberg, F. Cubic phase nanoparticles (cubosome): Principles for controlling size, structure, and stability. Langmuir？2005, 21, 2569–2577, doi:10.1021/la047590p.
[270]
Boomer, J.A.; Qualls, M.M.; Inerowicz, H.D.; Haynes, R.H.; Patri, V.S.; Kim, J.M.; Thompson, D.H. Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. Bioconjugate Chem.？2009, 20, 47–59, doi:10.1021/bc800239b.
[271]
Boyd, B.J. Characterisation of drug release from cubosomes using the pressure ultrafiltration method. Int. J. Pharm.？2003, 260, 239–247, doi:10.1016/S0378-5173(03)00262-X.
[272]
Briggs, J.; Chung, H.; Caffrey, M. The temperature-composition phase diagram and mesophase structure characterization of the monoolein/water system. J. Phys. II？1996, 6, 723–751, doi:10.1051/jp2:1996208.
[273]
Gustafsson, J.; Ljusberg-Wahren, H.; Almgren, M.; Larsson, K. Submicron particles of reversed lipid phases in water stabilized by a nonionic amphiphilic polymer. Langmuir？1997, 13, 6964–6971, doi:10.1021/la970566+.
[274]
Hyde, S.T. Bicontinuous structures in lyotropic liquid crystals and crystalline hyperbolic surfaces. Curr. Opin. Solid State Mat. Sci.？1996, 1, 653–662, doi:10.1016/S1359-0286(96)80047-7.
[275]
Larsson, K. Cubic lipid-water phases—Structures and biomembrane aspects. J. Phys. Chem.？1989, 93, 7304–7314.
[276]
Angelova, A.; Angelov, B.; Papahadjopoulos-Sternberg, B.; Ollivon, M.; Bourgaux, C. Structural organisation of proteocubosome carriers involving medium- and large-size proteins. J. Drug Deliv. Sci. Tech.？2005, 15, 108–112.
[277]
Angelova, A.; Angelov, B.; Lesieur, S.; Mutafchieva, R.; Ollivon, M.; Bourgaux, C.; Willumeit, R.; Couvreur, P. Dynamic control of nanofluidic channels in protein drug delivery vehicles. J. Drug Deliv. Sci. Tech.？2008, 18, 41–45.
[278]
Angelov, B.; Angelova, A.; Papahadjopoulos-Sternberg, B.; Lesieur, S.; Sadoc, J.-F.; Ollivon, M.; Couvreur, P. Detailed structure of diamond-type lipid cubic nanoparticles. J. Am. Chem. Soc.？2006, 128, 5813–5817.
[279]
Angelov, B.; Angelova, A.; Garamus, V.M.; Le Bas, G.; Lesieur, S.; Ollivon, M.; Funari, S.S.; Willumeit, R.; Couvreur, P. Small-angle neutron and X-ray scattering from amphiphilic stimuli-responsive diamond type bicontinuous cubic phase. J. Am. Chem. Soc.？2007, 129, 13474–13479.
[280]
Leesajakul, W.; Nakano, M.; Taniguchi, A.; Handa, T. Interaction of cubosomes with plasma components resulting in the destabilization of cubosomes in plasma. Colloid Surf. B Biointerfaces？2004, 34, 253–258.
[281]
Luzzati, V. Biological significance of lipid polymorphism: The cubic phases—Commentary. Curr. Opin. Struct. Biol.？1997, 7, 661–668, doi:10.1016/S0959-440X(97)80075-9.
[282]
Martins, S.; Sarmento, B.; Ferreira, D.C.; Souto, E.B. Lipid-based colloidal carriers for peptide and protein delivery—liposomes versus lipid nanoparticles. Int. J. Nanomed.？2007, 2, 595–607.
[283]
Nylander, T.; Mattisson, C.; Razumas, V.; Miezis, Y.; Hakansson, B. A study of entrapped enzyme stability and substrate diffusion in a monoglyceride-based cubic liquid crystalline phase. Colloid Surf. A Physicochem. Eng. Asp.？1996, 114, 311–320.
[284]
Qiu, H.; Caffrey, M. The phase diagram of the monoolein/water system: Metastability and equilibrium aspects. Biomaterials？2000, 21, 223–234, doi:10.1016/S0142-9612(99)00126-X.
[285]
Angelov, B.; Angelova, A.; Vainio, U.; Garamus, V.M.; Lesieur, S.; Willumeit, R.; Couvreur, P. Long living intermediates during a lamellar to a diamond-cubic lipid phase transition: A SAXS investigation. Langmuir？2009, 25, 3734–3742.
[286]
Angelov, B.; Angelova, A.; Mutafchieva, R.; Lesieur, S.; Vainio, U.; Garamus, V.M.; Jensen, G.V.; Pedersen, J.S. SAXS investigation of a cubic to a sponge (L3) phase transition in self-assembled lipid nanocarriers. Phys. Chem. Chem. Phys.？2011, 13, 3073–3081.
[287]
Angelova, A.; Angelov, B.; Garamus, V.M.; Couvreur, P.; Lesieur, S. Small-angle X-ray scattering investigations of biomolecular confinement, loading, and release from liquid crystalline nanochannel assemblies. J. Phys. Chem. Lett.？2012, 3, 445–457.
[288]
Angelov, B.; Angelova, A.; Papahadjopoulos-Sternberg, B.; Hoffmann, S.V.; Nicolas, V.; Lesieur, S. Protein-containing PEGylated cubosomic particles: Freeze-fracture electron microscopy and synchrotron radiation circular dichroism study. J. Phys. Chem. B？2012, 116, 7676–7686.
[289]
Angelova, A.; Angelov, B.; Mutafchieva, R.; Lesieur, S.; Couvreur, P. Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery. Acc. Chem. Res.？2011, 44, 147–156, doi:10.1021/ar100120v.
[290]
Siekmann, B.; Bunjes, H.; Koch, M.M.H.; Westesen, K. Preparation and structural investigations of colloidal dispersions prepared from cubic monoglyceride-water phases. Int. J. Pharm.？2002, 244, 33–43, doi:10.1016/S0378-5173(02)00298-3.
[291]
Yaghmur, A.; Glatter, O. Characterization and potential applications of nanostructured aqueous dispersions. Adv. Colloid Interface Sci.？2009, 147*#x2013;148, 333–342, doi:10.1016/j.cis.2008.07.007.
[292]
Al-jamal, W.T.; Kostarelos, K. Liposomes: From a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res.？2011, 44, 1094–1104, doi:10.1021/ar200105p.
[293]
Angelova, A.; Angelov, B.; Drechsler, M.; Garamus, V.M.; Lesieur, S. Protein entrapment in PEGylated lipid nanoparticles. Int. J. Pharm.？2013. submitted for publication.
[294]
Martina, M.S.; Fortin, J.P.; Ménager, C.; Clément, O.; Barratt, G.; Grabielle-Madelmont, C.; Gazeau, F.; Cabuil, V.; Lesieur, S. Generation of superparamagnetic liposomes revealed as highly efficient MRI contrast agents for in vivo imaging. J. Am. Chem. Soc.？2005, 127, 10676–10685.
[295]
Martina, M.S.; Wilhelm, C.; Lesieur, S. The effect of magnetic targeting on the uptake of magnetic-fluid-loaded liposomes by human prostatic adenocarcinoma cells. Biomaterials？2008, 29, 4137–4145, doi:10.1016/j.biomaterials.2008.07.011.
[296]
Lesieur, S.; Gazeau, F.; Luciani, N.; Ménager, C.; Wilhelm, C. Multifunctional nanovectors based on magnetic nanoparticles coupled with biological vesicles or synthetic liposomes. J. Mater. Chem.？2011, 21, 14387–14393.
